Multiplex Assay Kit for Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay)

CD182; CDw128b; IL8R-B; IL8-RB; CMKAR2; CXCR2; IL8R2; C-X-C chemokine receptor type 2; GRO/MGSA receptor; High affinity interleukin-8 receptor B

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 83-105 92
EDTA plasma(n=5) 90-97 94
heparin plasma(n=5) 78-104 98

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 97-105% 92-101% 78-92% 79-97%
EDTA plasma(n=5) 78-98% 85-99% 97-105% 89-104%
heparin plasma(n=5) 95-103% 98-105% 89-102% 83-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:IL8Rb) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Theranostics Direct Macromolecular Drug Delivery to Cerebral Ischemia Area using Neutrophil-Mediated Nanoparticles. pubmed:28900508
Scientific Reports Role of ceramide synthase 2 in G-CSF signaling and G-CSF-R translocation into detergent-resistant membranes Pubmed: 30679689
Pathogenic Functions of Tumor Necrosis Factor Receptor-associated Factor 6 Signaling following Traumatic Brain Injury
The neuroprotection of hyperbaric oxygen therapy against traumatic brain injury via NF-¦ÊB/MAPKs-CXCL1 signaling pathway
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPC006Mu02 Recombinant Interleukin 8 Receptor Beta (IL8Rb) Positive Control; Immunogen; SDS-PAGE; WB.
RPC006Mu01 Recombinant Interleukin 8 Receptor Beta (IL8Rb) Positive Control; Immunogen; SDS-PAGE; WB.
SPC006Mu01 Synthetic Interleukin 8 Receptor Beta (IL8Rb) Immunogen; Blocking Peptide.
CPC006Mu21 OVA Conjugated Interleukin 8 Receptor Beta (IL8Rb) Immunogen; SDS-PAGE; WB.
PAC006Mu01 Polyclonal Antibody to Interleukin 8 Receptor Beta (IL8Rb) WB; IHC; ICC; IP.
PAC006Mu08 Polyclonal Antibody to Interleukin 8 Receptor Beta (IL8Rb) WB; IHC; ICC; IP.
PAC006Mu02 Polyclonal Antibody to Interleukin 8 Receptor Beta (IL8Rb) WB; IHC; ICC; IP.
SEC006Mu ELISA Kit for Interleukin 8 Receptor Beta (IL8Rb) Enzyme-linked immunosorbent assay for Antigen Detection.
LMC006Mu Multiplex Assay Kit for Interleukin 8 Receptor Beta (IL8Rb) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.